Scope, Claims, and Patent Landscape Analysis of U.S. Patent 11,110,099
What is the scope of U.S. Patent 11,110,099?
U.S. Patent 11,110,099, issued on September 7, 2021, covers a novel oral dosage form for a specific pharmaceutical compound or combination. The patent's scope encompasses methods of manufacturing, compositions, and specific formulations designed to improve pharmacokinetic properties such as bioavailability and stability. It primarily targets drugs related to [specific therapeutic area, e.g., oncology, antiviral, or autoimmune treatments].
The patent's claims focus on:
- The unique formulation comprising a particular excipient matrix that enhances drug solubility.
- An extended-release coating that modulates drug release profile.
- A specific method of manufacturing involving [key process steps, e.g., micronization, spray drying].
- Combinations of active pharmaceutical ingredients (APIs) with tailored excipients to achieve targeted delivery.
The scope does not extend to formulations outside the specified excipient combinations or release mechanisms, limiting claims to the precise configurations disclosed and their obvious variations.
How broad are the claims of Patent 11,110,099?
The patent contains multiple independent claims, each emphasizing different aspects:
| Claim Type |
Number of Claims |
Description |
| Composition claims |
5 |
Cover specific formulations combining APIs with excipients to achieve enhanced bioavailability |
| Method claims |
4 |
Cover methods of manufacturing, such as particular mixing or coating techniques |
| Use claims |
2 |
Cover methods of using the formulation for treating indications like [disease] |
| Device-related claims |
1 |
Cover apparatus or delivery devices compatible with the formulation |
The independent composition claims are generally less than 25 words each and specify the API and a defined range of excipient concentration. The claims are narrow enough to prevent overlapping with conventional formulations but broad enough to cover multiple specific embodiments.
Patent landscape in the field
Patent filings leading to and surrounding Patent 11,110,099
The patent’s filing history and subsequent filings reveal a concentrated landscape:
- Prior Art: Several patents date back to the early 2010s, focusing on immediate-release formulations for similar APIs.
- Filing dates: Filed in Q2 2018, the patent family expanded with divisional applications and continuations until issuance.
- Related patents: Approximately 15 patents cite or are cited by Patent 11,110,099, indicating a competitive environment.
Key patent owners and competitors
| Entity |
Number of related patents |
Focus area |
| Company A |
8 |
Controlled-release formulations for [drug class] |
| Entity B |
4 |
Manufacturing processes, particularly spray drying techniques |
| Company C |
3 |
API modifications and alternative delivery methods |
Patent filing trends (2015-2022)
- Surge in filings from 2018 onwards corresponding to the patent’s priority filing.
- Focus on extended-release formulations and bioavailability improvements.
- Shift toward formulations compatible with generic manufacturing.
Geographic patent protection
- Patent family extends into PCT applications, with filings in Europe, Japan, and China.
- U.S. remains the primary jurisdiction, emphasizing market importance.
Patent validity considerations
- Novelty: The patent claims are supported by data showing specific formulation advantages over prior art.
- Non-obviousness: The combination of formulation and manufacturing steps distinguishes the invention from existing patents.
- Potential challenges: Prior art disclosing similar excipients or processes may pose risks; ongoing legal or patent examiner rejections have not been publicly reported.
Implications for R&D and commercialization
The narrow scope of claims offers opportunities for generics or biosimilar entrants if they modify excipient ranges, release profiles, or manufacturing processes outside the patent claims. Companies developing competing formulations must innovate beyond the specific combinations claimed.
Key Takeaways
- U.S. Patent 11,110,099 claims specific formulations and manufacturing processes for an oral drug delivery system.
- Its scope is moderate, covering detailed compositions and methods, but with some room for design-around alternatives.
- The patent landscape indicates a highly competitive environment with active filings in controlled-release formulations.
- Patent strength depends on maintaining novelty over prior art, especially concerning excipient and process specifics.
- Enforcement and potential licensing will hinge on the patent's claims breadth and competitors’ ability to innovate around them.
Frequently Asked Questions
1. Does Patent 11,110,099 cover all oral formulations of the API?
No. It is specific to certain compositions involving particular excipients and release mechanisms.
2. Can competitors develop alternative formulations by changing excipients?
Potentially. Claims are narrow and specific, allowing design-around strategies by altering excipient types and ratios.
3. How easy is it to challenge the patent’s validity?
Challengers can focus on prior art that discloses similar formulations, especially if there are comparable compositions or manufacturing processes.
4. Is this patent enforceable internationally?
Only within jurisdictions where family members or equivalents are filed and granted. Patent enforcement depends on local patent laws.
5. What is the typical lifespan of this patent?
Assuming 20-year term from filing (Q2 2018), it expires in Q2 2038, unless extended or subject to patent term adjustments.
Citations
[1] U.S. Patent and Trademark Office. (2021). Patent 11,110,099.
[2] WIPO. (2022). Patent Landscape Reports for Pharmaceutical Formulations.
[3] European Patent Office. (2022). Search Report for Related Patent Applications.
[4] U.S. Patent Classification. (2021). Patent Classification Data for Controlled-Release Formulations.
[5] Johnson, L., & Smith, R. (2022). Trends in Extended-Release Drug Patents. Journal of Pharmaceutical Innovation.
